These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 27979574)

  • 1. Apelin/APJ system: A bifunctional target for cardiac hypertrophy.
    Lu L; Wu D; Li L; Chen L
    Int J Cardiol; 2017 Mar; 230():164-170. PubMed ID: 27979574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.
    Parikh VN; Liu J; Shang C; Woods C; Chang AC; Zhao M; Charo DN; Grunwald Z; Huang Y; Seo K; Tsao PS; Bernstein D; Ruiz-Lozano P; Quertermous T; Ashley EA
    Am J Physiol Heart Circ Physiol; 2018 Aug; 315(2):H348-H356. PubMed ID: 29775410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apelin/APJ system: A novel promising target for anti-aging intervention.
    Zhou Q; Chen L; Tang M; Guo Y; Li L
    Clin Chim Acta; 2018 Dec; 487():233-240. PubMed ID: 30296443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APJ acts as a dual receptor in cardiac hypertrophy.
    Scimia MC; Hurtado C; Ray S; Metzler S; Wei K; Wang J; Woods CE; Purcell NH; Catalucci D; Akasaka T; Bueno OF; Vlasuk GP; Kaliman P; Bodmer R; Smith LH; Ashley E; Mercola M; Brown JH; Ruiz-Lozano P
    Nature; 2012 Aug; 488(7411):394-8. PubMed ID: 22810587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apelin/APJ system: A potential therapeutic target for endothelial dysfunction-related diseases.
    Cheng J; Luo X; Huang Z; Chen L
    J Cell Physiol; 2019 Aug; 234(8):12149-12160. PubMed ID: 30585633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel pathogenesis: regulation of apoptosis by Apelin/APJ system.
    Liu J; Liu M; Chen L
    Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):471-478. PubMed ID: 28407045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apelin/ELABELA-APJ system in cardiac hypertrophy: Regulatory mechanisms and therapeutic potential.
    Pang B; Jiang YR; Xu JY; Shao DX; Hao LY
    Eur J Pharmacol; 2023 Jun; 949():175727. PubMed ID: 37062502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apelin/APJ system: A critical regulator of vascular smooth muscle cell.
    Luo X; Liu J; Zhou H; Chen L
    J Cell Physiol; 2018 Jul; 233(7):5180-5188. PubMed ID: 29215755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The apelin/APJ system as a therapeutic target in metabolic diseases.
    Castan-Laurell I; Masri B; Valet P
    Expert Opin Ther Targets; 2019 Mar; 23(3):215-225. PubMed ID: 30570369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apelin/APJ system: A novel therapeutic target for locomotor system diseases.
    Luo J; Liu W; Feng F; Chen L
    Eur J Pharmacol; 2021 Sep; 906():174286. PubMed ID: 34174264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gαi-biased apelin analog protects against isoproterenol-induced myocardial dysfunction in rats.
    Coquerel D; Delile E; Dumont L; Chagnon F; Murza A; Sainsily X; Salvail D; Sarret P; Marsault E; Auger-Messier M; Lesur O
    Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1646-H1656. PubMed ID: 33635165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The apelin/APJ system in the regulation of vascular tone: friend or foe?
    Rikitake Y
    J Biochem; 2021 Apr; 169(4):383-386. PubMed ID: 33169143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
    Sato T; Sato C; Kadowaki A; Watanabe H; Ho L; Ishida J; Yamaguchi T; Kimura A; Fukamizu A; Penninger JM; Reversade B; Ito H; Imai Y; Kuba K
    Cardiovasc Res; 2017 Jun; 113(7):760-769. PubMed ID: 28371822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterodimerization of apelin and opioid receptors and cardiac inotropic and lusitropic effects of apelin in 2K1C hypertension: Role of pERK1/2 and PKC.
    Rostamzadeh F; Najafipour H; Yeganeh-Hajahmadi M; Esmaeili-Mahani S; Joukar S; Iranpour M
    Life Sci; 2017 Dec; 191():24-33. PubMed ID: 28987634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactation Is a Risk Factor of Postpartum Heart Failure in Mice with Cardiomyocyte-specific Apelin Receptor (APJ) Overexpression.
    Murata K; Ishida J; Ishimaru T; Mizukami H; Hamada J; Saito C; Fukamizu A
    J Biol Chem; 2016 May; 291(21):11241-51. PubMed ID: 27033703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apelin/APJ system as a therapeutic target in diabetes and its complications.
    Hu H; He L; Li L; Chen L
    Mol Genet Metab; 2016 Sep; 119(1-2):20-7. PubMed ID: 27650065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apelin/APJ system: an emerging therapeutic target for neurological diseases.
    Li A; Zhao Q; Chen L; Li Z
    Mol Biol Rep; 2023 Feb; 50(2):1639-1653. PubMed ID: 36378421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.
    Kuba K; Sato T; Imai Y; Yamaguchi T
    Peptides; 2019 Jan; 111():62-70. PubMed ID: 29684595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (3R)‑5,6,7‑trihydroxy‑3‑isopropyl‑3‑methylisochroman‑1‑one attenuates cardiac dysfunction via the apelin/APJ signaling pathway.
    Ding M; Guan L; Zhang C; Yang P; Yang H
    Mol Med Rep; 2019 Jun; 19(6):5007-5014. PubMed ID: 30942406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apelin/APJ system: an emerging therapeutic target for respiratory diseases.
    Yan J; Wang A; Cao J; Chen L
    Cell Mol Life Sci; 2020 Aug; 77(15):2919-2930. PubMed ID: 32128601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.